Windlas Biotech Limited has informed the Exchange regarding a press release dated May 22, 2025, titled "Windlas Biotech Limited Reports its Q4 and FY25 Financial Results".
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported its 9th straight quarter of record revenue, with FY25 revenue at Rs. 759.9 crores (up 20.4% YoY) and Q4 FY25 revenue at Rs. 202.7 crores (up 18.3% YoY). FY25 EBITDA grew 20.4% YoY to Rs. 94.1 crores with a margin of 12.4%, while Q4 EBITDA rose 16.3% to Rs. 25.5 crores. Net profit for FY25 stood at Rs. 61.0 crores (up 4.8% YoY), though Q4 PAT dipped slightly to Rs. 16.3 crores vs Rs. 17.0 crores a year ago. The company posted its highest-ever post-listing EPS of Rs. 29.19, with ROCE at 25% and ROE at 23%. All three verticals grew, led by Trade Generics at 41% YoY, while the board proposed a Rs. 5.8/share dividend for FY25.
Strong topline and EBITDA growth, healthy return ratios above 20%, and a record EPS signal solid operational momentum, though the slight Q4 PAT dip and rising depreciation from capacity expansion may temper near-term enthusiasm. The proposed dividend and new Plant-2/Injectable capacity utilisation point to continued growth visibility.